Search

everythinglearnresearchcommunity

for

Search:↓

Some hair loss and prostate drugs might increase the risk of diabetes and heart disease.

Dutasteride may reduce insulin sensitivity and increase body fat.

Choosing the right estroprogestin is crucial for effectively managing PCOS symptoms.

11β-Hydroxylase inhibitors help prevent seizures in mice by boosting natural neurosteroid production.

Prostaglandin E2 helps prevent hair loss from radiotherapy by protecting hair growth cells and aiding self-repair.

New drugs face challenges due to limited evidence, and safety updates are advised for some existing medications.

A three-month treatment with a GnRH agonist significantly lowered androgen levels and 5α-reductase activity in men with benign prostatic hyperplasia.

Hormonal contraceptives may reduce social behavior and sexual motivation by lowering allopregnanolone levels.

Neurosteroids may help treat disorders with too much dopamine activity.

Steroid sulfatase inhibitors could potentially treat hormone-related disorders like certain cancers, hair loss, acne, and improve cognitive dysfunction.

Blocking the enzyme 11β-HSD1 might help treat obesity and metabolic issues.

Certain medications can reduce mortality risk in COPD patients, but others can increase risks of cardiovascular issues, postoperative delirium, and other adverse effects.

Finasteride may help reduce impulsivity caused by pramipexole.

Two non-steroidal antiandrogens, RU 58841 and RU 56187, form a common metabolite at different rates, which may influence their effects; RU 56187 could be used for prostate cancer treatment and RU 58841 for acne treatment.

Steroidogenesis inhibitors change but don't stop androgen production in prostate cancer.

Drugs for hormone-related conditions might help treat mental disorders but could have serious side effects.

Finasteride slows down motherly behavior in first-time pregnant rats.

PNU 157706 is a more effective treatment than finasteride for conditions caused by DHT, like enlarged prostate and hair loss.

The document concludes that Catalyst software is effective for drug design, identifying potent compounds for various medical conditions.

Finasteride reduces certain behaviors caused by D1-like receptor agonists but not by D2-like receptor agonists in mice.

Therapies targeting the androgen receptor are being developed to treat prostate cancer and improve bone and muscle health.

PDE5 inhibitors cause earlier adverse events in BPH treatment, requiring careful monitoring.

A brominated phenoxy compound effectively inhibits a human enzyme and shows potential for clinical use.

Sex steroids, especially progesterone, can slow down the growth of mouse melanoma cells.

Dutasteride effectively treats benign prostatic hyperplasia but isn't approved for preventing prostate cancer.

Progesterone and related compounds may help control seizures linked to the menstrual cycle but have limitations that need addressing.

Minoxidil and ranolazine together can reduce the spread of certain breast cancer cells.

Including androgens in hormone therapy may lower breast cancer risk.

Tadalafil and Finasteride may help treat aggressive melanoma.